CAR T-cell therapy for triple-negative breast cancer: Where we are

Triple-negative breast cancer (TNBC) is the most complex and challenging breast cancer subtype to treat, and chemotherapy remains the standard of care. Clinically, TNBC has a relatively high rate of recurrence and poor prognosis, which leads to a significant effort to discover novel strategies to tr...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer letters Vol. 491; pp. 121 - 131
Main Authors:	Xie, Yuetao, Hu, Yi, Zhou, Nawu, Yao, Cuicui, Wu, Lixin, Liu, Lin, Chen, Fang
Format:	Journal Article
Language:	English
Published:	Ireland Elsevier B.V 28-10-2020 Elsevier Limited
Subjects:	Antigen (tumor-associated) Antigens Antigens, Neoplasm - immunology Antitumor activity Breast cancer Cancer therapies Cell therapy Chemotherapy Chimeric antigen receptor Chimeric antigen receptors Chondroitin Sulfate Proteoglycans - immunology Clinical trials Cytotoxicity Female Folate Receptor 1 - immunology GPI-Linked Proteins - immunology Humans Immune system Immunotherapy Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Intercellular Adhesion Molecule-1 - immunology Leukemia Lymphocytes Lymphocytes T Medical prognosis Membrane Proteins - immunology Mucin-1 - immunology NK Cell Lectin-Like Receptor Subfamily K - immunology Receptor Tyrosine Kinase-like Orphan Receptors - immunology T cell receptors T cells Toxicity Triple Negative Breast Neoplasms - therapy Triple-negative breast cancer Tumor antigens Tumor cells Tumors Vectors (Biology) Chimeric antigen receptor T cells Immunotherapy Tumor antigens Triple-negative breast cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Triple-negative breast cancer (TNBC) is the most complex and challenging breast cancer subtype to treat, and chemotherapy remains the standard of care. Clinically, TNBC has a relatively high rate of recurrence and poor prognosis, which leads to a significant effort to discover novel strategies to treat patients with these tumors. Currently, chimeric antigen receptor (CAR) T cell-based immunotherapy redirects the patient's immune system directly to recognize and eradicate tumor-associated antigens (TAAs) expressing tumor cells being explored as a treatment for TNBC. A steadily increasing research in CAR T-cell therapy targeting different TAAs in TNBC has reported. In this review, we introduce the CAR technology and summarize the potential TAAs, available CARs, the antitumor activity, and the related toxicity of CARs currently under investigation for TNBC. We also highlight the potential strategies to prevent/reduce potential “on target, off tumor” toxicity induced by CAR T-cell therapy. This review will help to explore proper targets to expand further the CAR T-cell therapy for TNBCs in the clinic. •TNBC is the most complex and challenging breast cancer subtype.•CAR T cell-based immunotherapy is being explored as a treatment for TNBC.•The judicious selection of the target antigens is critical to the success of CAR T-cell therapy.•Improving the safety of CAR T-cell therapy is extremely important.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2020.07.044